News ArchivesRead News
Seattle PI Special Parkinson’s Report
Tuesday April 03, 2001
Overnight, addicts get Parkinson’s, scientists get breakthrough
By CAROL SMITH P-I REPORTER
April 1, 1999 - Dr. Phil Ballard had seen all sorts of bizarre patients in psychiatric emergency rooms. But he’d never seen one like George Carillo.
It was 1982, and Ballard - now head of the Movement Disorder Program at Swedish Medical Center - was completing a neurology fellowship at Stanford University. He’d been called in to consult on a 42-year-old man who sat frozen mid-gesture, unblinking and lifeless except for normal organ function. There was no evidence of mental activity.
"He had a blank stare and was stiff as a board," Ballard said. Since the patient had come from jail, many doctors who saw him suspected he was faking catatonic schizophrenia to get out of trouble.
But it was no act.
After seven days with no change and no diagnosis, Ballard noticed a slight twitching in the man’s fingers. He slipped him a pad and pencil.
"I’m not sure what is happening to me," the patient wrote, using just his fingertips. "I can’t move right. I know what I want to do. It just won’t come out right."
Ballard was elated to discover a normal mind trapped inside the body. Slowly, he pieced together the patient’s history. The patient and his girlfriend were heroin addicts. They’d come down with symptoms after injecting a street-synthesized version of Demerol, a "designer drug" meant to act like heroin.
With that information in hand, Ballard and his boss, Dr. J. William Langston, set out to solve the mystery of one patient and ended up making a major breakthrough in the study of Parkinson’s disease.
Over the next few weeks, more addicts in strangely frozen postures began turning up in emergency rooms all over the San Francisco Bay area. They had one thing in common. Each had been using designer street narcotics.
Investigators suspected a bad batch caused the outbreak, but they couldn’t identify the contaminant.
Then, by chance, one of the team recalled reading an obscure journal report years earlier of a young college student who had ended up with identical symptoms after synthesizing his own drugs in 1976. After he died 18 months later, an autopsy revealed the distinctive brain damage associated with Parkinson’s disease. Until then, doctors had almost never seen Parkinson’s in someone so young. And they’d never seen it develop overnight.
Ballard set out to find the article, which wasn’t even in the medical center library. "I dug it out of the dusty reaches of the racks of Stanford library," he said. "I realized as I was reading it that this is it, this has got to be it."
Indeed, it turned out that a contaminant called MPTP caused both the college student’s symptoms and those of the street addicts.
MPTP can slip across the blood-brain barrier, where it kills the dopamine-producing cells in the brain. A dopamine shortage leads to Parkinson’s.
In their quest for a new high, the addicts had inadvertently given themselves an irreversible, debilitating disease. But they gave the scientific community something else: a clue to what causes Parkinson’s disease. MPTP resembles many environmental chemicals, including pesticides, which led to the now widely accepted theory that toxins induce Parkinson’s.
In addition to providing a key breakthrough in understanding the disease, MPTP gave researchers a way to induce Parkinson’s disease in animals, giving them for the first time a model for testing new drugs and other therapies.
Several of the original addicts received experimental treatments, such as fetal cell implants, that grew out of that research. In some cases, it dramatically improved their symptoms, allowing them to resume a more normal life.
"It was quite a chase," Ballard said. "We had a lot of dead ends and a lot of lucky breaks."
P-I reporter Carol Smith can be reached at 206-448-8070 or via e-mail: <a href="mailto:firstname.lastname@example.org">email@example.com</a><P> <i>See the <a href="http://www.seattle-pi.com/local/park01.shtml">original special report</a> in the Seattle Post-Intelligencer
Recent NewsJun 26 - Do Statins Increase Risk of Parkinson’s Disease? Some Researchers Think So
Jun 22 - A Confused Immune System Could Be Behind Parkinson's Disease
Jun 21 - Predicting cognitive deficits in people with Parkinson’s disease
Jun 19 - Human Limitations Could Prevent Us From Advancing in Science. AI Could Help.
Jun 13 - Brain Cell Transplants Are Being Tested Once Again For Parkinson's
Jun 12 - Smell Test May Sniff Out Oncoming Parkinson's and Alzheimer's
Jun 8 - Smartphones Track Motor Function in Parkinson's Disease
Jun 8 - GKC Enrolls First Patient in Personal KinetiGraph Trial as Part of NPF’s Parkinson’s Outcomes Project
Jun 8 - Low-fat dairy intake may raise Parkinson's risk
Jun 6 - Patient Voices: Parkinson's Disease
Jun 1 - World-First Trials Have Been Launched to Treat Parkinson's And Blindness With Embryonic Stem Cells
Jun 1 - LIFE Shared This Remarkable Parkinson's Disease Story in 1959.
May 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?